RJA
ERNA icon

Raymond James & Associates’s Eterna Therapeutics ERNA Stock Holding History

Raymond James & Associates’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed -$67K – 4078
2022
Q1 		$67K Sell
4
-25
-86% -$474K ﹤0.01% 3886
2021
Q4 		$907K Buy
+29
New +$1.58M ﹤0.01% 2675
2016
Q2 		– Hold
0
– -$45K – 3041
2016
Q1 		– Hold
0
– – – 2794

Other funds holding ERNA

CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's ERNA Position: Q2 2022 in Review

Raymond James & Associates sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 4 shares — an estimated $67K sold.

Raymond James & Associates first reported a position in ERNA in Q4 2021 and held it in 2 quarters. The position peaked at $907K in Q4 2021. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

  • Raymond James & Associates reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 4 Eterna Therapeutics shares in Q2 2022, an estimated $67K.
  • Raymond James & Associates first reported a position in Eterna Therapeutics in Q4 2021 and held it in 2 quarters.
  • Raymond James & Associates's Eterna Therapeutics position peaked at $907K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.